Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an FDA-approved blood test for colorectal cancer screening, across its nationwide network. The agreement expands access ...
Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shieldâ„¢ by Guardant blood-based screening test is now widely accessible for physician order through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results